Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Rhea-AI Summary
Senseonics (NASDAQ: SENS) announced management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026 in Snowbird, Utah.
Investors seeking a meeting are advised to contact their BTIG representatives to request a meeting with Senseonics management.
Positive
- None.
Negative
- None.
News Market Reaction – SENS
In the Jan 29 session, SENS gained 2.05%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Prelim revenue, update | Positive | -1.5% | Record Q4 and 2025 revenue, strong 2026 guidance and business update. |
| Jan 08 | Product integration launch | Positive | +1.4% | First commercial patients using Eversense 365 with twiist AID system. |
| Nov 10 | Conference participation | Positive | +5.3% | Participation in Stifel 2025 Healthcare Conference and investor meetings. |
| Nov 10 | Exchange transfer | Positive | +5.3% | Transfer of stock listing from NYSE American to Nasdaq Global Select Market. |
| Nov 05 | Quarterly earnings | Positive | +0.6% | Q3 2025 revenue growth, improved gross profit, and narrowed net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally seen positive reactions: 4 of 5 prior announcements with positive fundamentals or strategic updates led to gains, with one "sell-the-news" dip on strong preliminary revenue.
Over the last few months, Senseonics has reported strong growth, including preliminary Q4 2025 and full‑year revenue records, expanded guidance, and a move to the Nasdaq Global Select Market. Commercial milestones included the Eversense 365 integration with an AID system and participation in major healthcare conferences. Earnings showed improving revenue and margins. Today’s BTIG conference participation continues the pattern of active investor outreach and visibility around its long‑term implantable CGM platform.
Key Terms
continuous glucose monitoring (CGM) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah.
To request a meeting with Senseonics, investors should contact their BTIG representatives.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
